|Bid||0.0000 x 800|
|Ask||0.0000 x 2200|
|Day's Range||3.9000 - 4.1400|
|52 Week Range||2.7900 - 5.0000|
|Beta (3Y Monthly)||0.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.17|
ChromaDex Corp. (CDXC) announced today that its Chief Executive Officer, Rob Fried, Chairman and Co-Founder, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 31st annual ROTH Capital Partners Conference at the Ritz-Carlton in Dana Point, CA. The ChromaDex management team is scheduled to present on Monday, March 18, at 3:30 p.m. Pacific Time. ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day. For more information about the conference or to schedule a one-on-one meeting with ChromaDex management, please contact your ROTH representative.
ChromaDex Corp. (CDXC) announced today it will feature its cellular health product, TRU NIAGEN®, at SXSW®, as it marks the achievement of attaining over 160 research collaborations around the world on its patented NIAGEN® (nicotinamide riboside) ingredient. "To help SXSW® attendees who need an extra boost in their busy lives, we'll be providing samples of Tru Niagen and discussing the science that disrupted the multi-billion-dollar anti-aging category with the discovery of nicotinamide riboside by Dr. Charles Brenner," says Frank Jaksch, ChromaDex Co-Founder and Executive Chairman.
- Full Year 2018 Net Revenues Increased by 49% to $31.6 Million and Fourth Quarter 2018 Net Revenues Increased by 20% to $9.1 Million - Fourth Quarter 2018 Highlights vs..
ChromaDex Corp. (CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 39th Annual Cowen Heath Care Conference at the Boston Marriott Copley Place in Boston, MA. The ChromaDex management team is scheduled to present on Monday, March 11, at 4:50 p.m. ET. ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day.
LOS ANGELES, Feb. 28, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., Mar. 7, 2019 at 4:30 p.m. Eastern time to discuss its.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! ChromaDex Corporation (NASDAQ:CDXC), which is in the life sciences business,Read More...
ChromaDex Corp. (CDXC) today reported that results of a first-of-a-kind preclinical study on lactation have shown that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen) confers significant and enduring physiological benefits to mothers and offspring. Conducted at the University of Iowa by Principal Investigator Dr. Charles Brenner, the Roy J. Carver Chair & Head of Biochemistry at the University of Iowa, as well as a founding co-director of the University of Iowa Obesity Initiative and Chief Scientific Advisor of ChromaDex, the study results were published yesterday in the journal Cell Reports.
Elysium Health Inc. filed its petitions requesting inter partes review (IPR) of the 086 and 807 patents on July 17, 2017. ChromaDex (along with the Trustees of Dartmouth College) is now prepared to proceed with the patent infringement action against Elysium Health pending in the US District Court in Delaware brought by the parties under both the 086 and 807 patents.
Investing.com - CarMax, Chromadex and Intevac rallied into the close Friday despite a sea of red across Wall Street.
ChromaDex Corporation and Nestlé Health Science agreement includes global commercial license and supply agreement for ingredient sales of TRU NIAGEN® for certain products within the medical nutrition and consumer health categories. LOS ANGELES, Dec. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (CDXC) announced today it entered into a license and supply agreement with Nestlé Health Science (NHSc), a global leader pioneering quality science-based nutritional health solutions. The agreement provides NHSc the exclusive right to include CDXC’s patented nicotinamide riboside ingredient TRU NIAGEN® in NHSc branded medical nutrition, and co-exclusive rights to include TRU NIAGEN® in certain products within the consumer health category.
ChromaDex Corp. (CDXC) announced today it has officially launched TRU NIAGEN® in Canada, having received regulatory approval for sale by Health Canada. Directly from the innovators behind NIAGEN® (nicotinamide riboside), the product is now available at www.truniagen.ca and to healthcare practitioners at Fullscript Canada.
ChromaDex Corp. (CDXC) announced today it will feature TRU NIAGEN® (Booth #6095) at the American Academy of Anti-Aging Medicine World Congress, a gathering of physicians, researchers, and healthcare practitioners from Dec. 13-15 in Las Vegas, NV. Dr. Charles Brenner, ChromaDex Chief Scientific Advisor and the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, will be presenting "How to Hack Your NAD: Scientifically Validated Strategies for Resisting Stress and Aging Better" at 4:30pm PST on Dec. 13 in the Exhibit Hall, Product Theatre Stage. The discussion on NAD and biohacking will continue on Friday, Dec. 14 from 3:45-4:15pm PST at the TRU NIAGEN® booth—Dave Asprey, Founder & CEO of Bulletproof, will be signing complimentary copies of his new book, Game Changers: What Leaders, Innovators, and Mavericks Do to Win at Life—come early as quantities are limited.
ChromaDex Corp. (CDXC) announced today that its Chief Executive Officer, Rob Fried, Co-Founder & Executive Chairman, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 11th annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. The ChromaDex management team is scheduled to present on Wed., Dec. 5, 2018, at 4:30 p.m. PST. ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day. ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age.
ChromaDex Corp. (CDXC) announced today the launch of TRU NIAGEN stick packs, offering a new delivery method of its revolutionary nicotinamide riboside ingredient to promote cellular energy and repair. The stick packs, which each provide 300mg nicotinamide riboside mixed with fiber source inulin (chicory root extract), will offer consumers single-serving packets that easily mix into both cold and hot beverages, including smoothies and coffee. “We are pleased to introduce this new way to ingest Tru Niagen,” says ChromaDex CEO Rob Fried.
ChromaDex (CDXC) delivered earnings and revenue surprises of -33.33% and -9.78%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Irvine, California-based company said it had a loss of 16 cents. The natural products company posted revenue of $8.1 million in the period. In the final minutes of trading on ...
ChromaDex Corp. (CDXC) announced today that it has appointed Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation, effective immediately. Roberts brings over 30 years of experience in scientific innovation and product development, launching hundreds of products while building global R&D teams.
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LOS ANGELES, Oct. 31, 2018 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., Nov. 7, 2018 at 4:30 p.m. Eastern time to discuss its.